|
Sorted by: Date | Top Results
|
|
Author |
|
Date |
| |
| |
| 1. |
Re: Play the Q4 Angiotech income game!!! 
My guess. Proprietary (Quill, etc.): Q2-->$13.5
million Q3-->$14.7 million-->Q4 $17.2 million
Base (Needles, Opthalmic, Dental, OEM) Q2-->$33.7
million Q3-->$34.0 million-->Q4 $35.5 million
Royalty (Taxus with Boston Scientific and Cook) Q
2...
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Angiotech Pharmaceuticals, Inc.
|
|
scistats |
|
5-Feb-10 07:54 pm |
| |
| 2. |
Play the Q4 Angiotech income game!!!
To play, predict Q4 2009 values before March 4th 8:00
AM ET (5:00 AM Pacific) Proprietary (Quill, etc.):
Q2-->$13.5 million Q3-->$14.7 million-->Q4
? million Base (Needles, Opthalmic, Dental, OEM)
Q2-->$33...
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Angiotech Pharmaceuticals, Inc.
|
|
scistats |
|
5-Feb-10 07:44 pm |
| |
| 3. |
Re: Perhaps....
Assets (Quill) + Liabilities (AMI Debt) = ~$0.00 Ethicon
or Covidien would be happy to pay $400-$500 million
for Quill, leaving almost no debt. ANPI better act
fast though. Its time to...
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Angiotech Pharmaceuticals, Inc.
|
|
scistats |
|
5-Feb-10 05:44 pm |
| |
| 4. |
Re: FINALLY....some new NEWS!!!!!!!!
If Broncus had materialized without complications,
there would have been a huge news release. This would
have put Taxus back on the map, big time. But, we
have...
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Angiotech Pharmaceuticals, Inc.
|
|
scistats |
|
4-Feb-10 05:05 pm |
| |
| 5. |
Re: Paclitaxel and zotarolimus similar safety, efficacy.
Bridge, you are preaching to the choir. I totally agree
with what you are saying. We need larger studies comparing
apples to apples and...
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Angiotech Pharmaceuticals, Inc.
|
|
scistats |
|
3-Feb-10 06:42 pm |
| |
| 6. |
Paclitaxel and zotarolimus similar safety, efficacy.
For what its worth, Taxus is still running with the
pack, and one begins to wonder about the legitimacy
of 1000-2000 patient studies. The 19,000 patient study
from the Swedish national registry...
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Angiotech Pharmaceuticals, Inc.
|
|
scistats |
|
3-Feb-10 12:01 pm |
| |
| 7. |
Re: BSX&&39;s Huge Settlement with JNJ is Good for ANPI
Yags, I think BSX has combinatorial data for Taxus
and everolimus on the same stent (lab data). The Taxus
patent is good for 7+ years to come. It expires in
2017+. If the drug...
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Angiotech Pharmaceuticals, Inc.
|
|
scistats |
|
2-Feb-10 02:09 pm |
| |
| 8. |
Why Zilver PTX is different...in Chinese.
http://www.tech-ex.com/equipment/news/mainland/00462873.html
Translation: "The latest of the Zilver ® PTX
® is different from the past, drug stent technology,
which without the use of adhesion of polymer to d
rug...
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Angiotech Pharmaceuticals, Inc.
|
|
scistats |
|
29-Jan-10 10:07 am |
| |
| 9. |
Re: Zilver PTX = ~5.1 million per quarter on the low end
We are first and goal, but the ball has to cross the
line before we see the points. Bio-Seal needs FDA
approval, Quill has to meet expectations, Zilver
PTX...
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Angiotech Pharmaceuticals, Inc.
|
|
scistats |
|
21-Jan-10 05:40 pm |
| |
| 10. |
JNJ Suit Against BSX Over
http://www.boston.com/business/technology/articles
/2010/01/21/boston_scientific_claims_patents_win/
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Angiotech Pharmaceuticals, Inc.
|
|
scistats |
|
21-Jan-10 03:30 pm |
| |
| 11. |
Zilver PTX = ~5.1 million per quarter on the low end
Zilver PTX will bring in conservatively 5.1 million
per quarter for ANPI, after NIH payments of 15%. Double
check my math: 150,000 patients per year, one stent
per patient, $2000.00 per stent, 8% royalty from Cook
Medical...
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Angiotech Pharmaceuticals, Inc.
|
|
scistats |
|
21-Jan-10 03:05 pm |
| |
| 12. |
Re: Johnson & Johnson Unit Sues Boston Scientific Over Stents
Wow, I thought they had settled this argument. Guess
not.
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Angiotech Pharmaceuticals, Inc.
|
|
scistats |
|
20-Jan-10 11:00 am |
| |
| 13. |
Re: Good News for ANPI: Medical Device Maker Tax Is History
Q. How do you describe the legislation in both the
House and Senate that would tax U.S. sales of medical
devices? A. The unfortunate thing about the tax is
it is based on your...
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Angiotech Pharmaceuticals, Inc.
|
|
scistats |
|
20-Jan-10 08:31 am |
| |
| 14. |
Re: Good News for ANPI: Medical Device Maker Tax Is History
http://www.medcitynews.com/index.php/2010/01/from-
absurdity-to-reality-medical-device-tax-jolts-inva
care-ceo-malachi-mixon/
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Angiotech Pharmaceuticals, Inc.
|
|
scistats |
|
20-Jan-10 08:26 am |
| |
| 15. |
Good News for ANPI: Medical Device Maker Tax Is History
Looks like the medical device maker tax is history.
Good news for ANPI.
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Angiotech Pharmaceuticals, Inc.
|
|
scistats |
|
20-Jan-10 08:20 am |
| |
| 16. |
Good news for Zilver PTX
http://eon.businesswire.com/portal/site/eon/permal
ink/?ndmViewId=news_view&newsId=20100119005313&new
sLang=en
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Angiotech Pharmaceuticals, Inc.
|
|
scistats |
|
19-Jan-10 03:25 pm |
| |
| 17. |
Three high level jobs on the ANPI board?
On Saturday Jan. 16th, three high level jobs were announced
on the ANPI job board? Are these new or refills? If
they are refills, why did...
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Angiotech Pharmaceuticals, Inc.
|
|
scistats |
|
18-Jan-10 12:45 am |
| |
| 18. |
Re: It feels like a hammer on the head
Yags, below is a recap of Quill's milestone requirements.
Indeed the milestone payments are rough, but we knew
this already, and Morningstar is just rehashing..
.
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Angiotech Pharmaceuticals, Inc.
|
|
scistats |
|
17-Jan-10 12:36 am |
| |
| 19. |
AMI MultiStem to Treat Heart Attacks...disclosure not until July-August?
Athersys Reports 2009 Third Quarter Results CLEVELAND,
Nov 5, 2009 "We completed the second dosing cohort
for the AMI study and are currently enrolling...
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Angiotech Pharmaceuticals, Inc.
|
|
scistats |
|
14-Jan-10 11:21 am |
| |
| 20. |
Re: $575 million debt load = SELL QUILL
We have a titanic like situation here. Either ANPI
sells Quill and pays off its debt, or the company
is going to sink like a ballast stone. It is a mathematical
certainty. However, I do believe ANPI...
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Angiotech Pharmaceuticals, Inc.
|
|
scistats |
|
13-Jan-10 05:32 am |
| |
